# ARROWHEAD PHARMACEUTICALS, INC. (ARWR) FY2026 Q3 Balance Sheet

- Company: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Period: As of 2026-06-30
- Filing: Q3 FY2026 10-Q, filed 2026-08-04, accession number 0000879407-26-000057
- Page: https://plicit.ai/financials/arwr/fy2026-q3-balance-sheet
- Chart image: https://plicit.ai/charts/arwr-fy2026-q3-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 2,112,013,000 US dollars
- **Current assets**: 1,671,411,000 US dollars
- **Non-current assets**: 440,602,000 US dollars
- **Liabilities (calculated)**: 1,645,972,000 US dollars
- **Current liabilities**: 283,346,000 US dollars
- **Non-current liabilities**: 1,362,626,000 US dollars
- **Equity**: 466,041,000 US dollars
- **Noncontrolling interest**: 512,000 US dollars. Included in consolidated equity; this amount is not added again.
- **Available-for-sale securities, at fair value**: 1,547,201,000 US dollars
- **Cash, cash equivalents and restricted cash**: 54,759,000 US dollars
- **Other current assets**: 35,522,000 US dollars
- **Prepaid expenses**: 25,373,000 US dollars
- **Accounts receivable**: 8,556,000 US dollars
- **Property, plant and equipment, net**: 373,301,000 US dollars
- **Right-of-use assets**: 55,667,000 US dollars
- **Other assets**: 6,048,000 US dollars
- **Intangible assets, net**: 5,586,000 US dollars
- **Deferred revenue**: 94,596,000 US dollars
- **Accrued expenses**: 86,174,000 US dollars
- **Credit facility**: 40,000,000 US dollars
- **Accounts payable**: 27,776,000 US dollars
- **Accrued payroll and benefits**: 23,455,000 US dollars
- **Other liabilities**: 6,023,000 US dollars
- **Lease liabilities**: 5,322,000 US dollars
- **Convertible Notes, Net**: 682,707,000 US dollars
- **Liability related to the sale of future royalties**: 392,512,000 US dollars
- **Credit facility, net of current portion**: 141,366,000 US dollars
- **Lease liabilities, net of current portion**: 114,298,000 US dollars
- **Deferred revenue, net of current portion**: 31,743,000 US dollars
- **Additional paid-in capital**: 2,443,074,000 US dollars
- **Common stock, $0.001 par value: Authorized 290,000 shares; 143,796 shares issued and 141,135 outstanding as of June 30, 2026 and 138,363 shares issued and 135,702 outstanding as of September 30, 2025**: 237,000 US dollars
- **Noncontrolling interest**: 512,000 US dollars
- **Accumulated deficit**: negative 1,923,355,000 US dollars
- **Treasury stock; at cost; 2,661 shares of common stock at June 30, 2026 and September 30, 2025**: negative 53,193,000 US dollars
- **Accumulated other comprehensive (loss) income**: negative 1,234,000 US dollars
- **Gross equity (calculated)**: 2,443,823,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.